30414-55-2 Usage
Description
5-Methyl-3-oxohexanoic acid methyl ester, also known as methyl 3-oxo-5-methylhexanoate, is a chemical compound with the molecular formula C8H14O3. It is derived from the esterification of 5-Methyl-3-oxohexanoic acid with methanol. 5-Methyl-3-oxohexanoic acid methyl ester is known for its fruity odor and has been studied for its potential biological activities, including antimicrobial and antioxidant properties.
Uses
Used in Organic Synthesis:
5-Methyl-3-oxohexanoic acid methyl ester is used as a building block in organic synthesis for the production of various pharmaceuticals, fragrances, and flavoring agents. Its versatile chemical structure allows for the creation of a wide range of compounds with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Methyl-3-oxohexanoic acid methyl ester is used as an intermediate in the manufacturing of other chemicals. Its unique properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Fragrance Industry:
5-Methyl-3-oxohexanoic acid methyl ester is used as a fragrance ingredient due to its fruity odor. It contributes to the creation of various scents in perfumes, cosmetics, and other scented products.
Used in Flavoring Agents:
5-Methyl-3-oxohexanoic acid methyl ester is also used in the food and beverage industry as a flavoring agent. Its fruity aroma enhances the taste and aroma of various food products, making them more appealing to consumers.
Used in Antimicrobial Applications:
5-Methyl-3-oxohexanoic acid methyl ester has been studied for its potential antimicrobial properties. It can be used as a natural preservative in various products to prevent the growth of harmful microorganisms.
Used in Antioxidant Applications:
The antioxidant properties of 5-Methyl-3-oxohexanoic acid methyl ester make it a potential candidate for use in products that require protection against oxidative damage, such as cosmetics, food products, and pharmaceuticals. Its ability to neutralize free radicals can help maintain the stability and shelf life of these products.
Check Digit Verification of cas no
The CAS Registry Mumber 30414-55-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,4,1 and 4 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 30414-55:
(7*3)+(6*0)+(5*4)+(4*1)+(3*4)+(2*5)+(1*5)=72
72 % 10 = 2
So 30414-55-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H14O3/c1-6(2)4-7(9)5-8(10)11-3/h6H,4-5H2,1-3H3
30414-55-2Relevant articles and documents
Characterization of FabG and FabI of the Streptomyces coelicolor dissociated fatty acid synthase
Singh, Renu,Reynolds, Kevin A.
, p. 631 - 640 (2015/03/31)
Streptomyces coelicolor produces fatty acids for both primary metabolism and for biosynthesis of the secondary metabolite undecylprodiginine. The first and last reductive steps during the chain elongation cycle of fatty acid biosynthesis are catalyzed by FabG and FabI. The S. coelicolor genome sequence has one fabI gene (SCO1814) and three likely fabG genes (SCO1815, SCO1345, and SCO1846). We report the expression, purification, and characterization of the corresponding gene products. Kinetic analyses revealed that all three FabGs and FabI are capable of utilizing both straight and branched-chain β-ketoacyl-NAC and enoyl-NAC substrates, respectively. Furthermore, only SCO1345 differentiates between ACPs from both biosynthetic pathways. The data presented provide the first experimental evidence that SCO1815, SCO1346, and SCO1814 have the catalytic capability to process intermediates in both fatty acid and undecylprodiginine biosynthesis.
Chemoenzymatic asymmetric synthesis of pregabalin precursors via asymmetric bioreduction of β-cyanoacrylate esters using ene-reductases
Winkler, Christoph K.,Clay, Dorina,Davies, Simon,O'Neill, Pat,McDaid, Paul,Debarge, Sebastien,Steflik, Jeremy,Karmilowicz, Mike,Wong, John W.,Faber, Kurt
, p. 1525 - 1533 (2013/04/10)
The asymmetric bioreduction of a library of β-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.
KINESIN INHIBITORS
-
Page/Page column 58, (2009/01/20)
This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder.